



## Effect of *Kelussia odoratissima* Mozaff essential oil on promastigot form of *Leishmania major* (in vitro)

Khodadad Pirali Kheirabadi<sup>1\*</sup>, Siavash Saei Dehkordi<sup>2</sup>, Parviz Kheibari<sup>3</sup>

<sup>1</sup>Department of pathobiology, Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, Iran

<sup>2</sup>Department of Food Hygiene and Quality Control, Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, Iran

<sup>3</sup>Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, Iran

### ARTICLE INFO

#### Article Type:

Original Article

#### Article History:

Received: 7 September 2014

Accepted: 14 December 2014

#### Keywords:

Essential oil

In vitro

*Kelussia odoratissima*

Leishmaniasis

Promastigot form

### ABSTRACT

**Introduction:** Leishmaniasis is a zoonotic disease caused by a protozoan of the genus *Leishmania*. In this study, the effects of *Kelussia odoratissima* Mozaff essential oil on the promastigot form of *Leishmania major* were studied.

**Methods:** In this study, the effects of *Kelussia odoratissima* Mozaff essential oil on the promastigot form of *Leishmania major* were assessed by calculating the average number of surviving promastigots after exposure to different concentrations of essential oil, relative to the control Glucantime, at different time intervals. To achieve this, various essential oil concentrations (7.5 µl, 15 µl, 25 µl, 35.25 µl, 50 µl) were added to parasites. Different groups in this study were kept in a 26°C incubator under identical conditions. 24, 48 and 72 hours after incubation, living promastigots were counted.

**Results:** The effect of the essential oil of *Kelussia odoratissima* Mozaff differed from the negative and positive controls and depended on the concentration: higher concentrations (35.25 µl, 50 µl) had a stronger effect on promastigots, causing total mortality.

**Conclusion:** This study showed that *Kelussia odoratissima* Mozaff essential oil had effects on promastigot form of *Leishmania major*. So it might be possible to use the essential oil of *Kelussia odoratissima* instead of chemical drugs.

### Implication for health policy/practice/research/medical education:

It is possible to use the essential oil of *Kelussia odoratissima* instead of chemical drugs. The use of any concentration of essential oil of *Kelussia odoratissima* controlled *L. major* more effectively by increasing in essential oil concentration. Future research would assess the effect of this essential oil on the amastigote form of *L. major*.

**Please cite this paper as:** Pirali Kheirabadi K, Saei Dehkordi S, Kheibari P. Effect of *Kelussia odoratissima* Mozaff essential oil on promastigot form of *Leishmania major* (in vitro). J HerbMed Pharmacol 2015; 4(1): 10-14.

### Introduction

Medicinal herbs contain physiologically active principles that have been exploited in traditional medicine for the treatment of various ailments due to their anti-microbial properties (1,2). The antifungal and antibacterial activity exhibited by extracts and essential oils of medicinal plants is well proved (3).

*Kelussia odoratissima* Mozaff. (wild celery; Apiaceae) is a sweet-smelling, glabrous, perennial aromatic herb, which is traditionally consumed in Iran and grows to a height of 120 to 200 cm. The flowers are 1-2 mm in diameter and all are hermaphroditic. *K. odoratissima* is an Iranian endemic plant native to Zagros (central region of Iran) (4).

*Kelussia* grows in April and its aerial parts are harvested (5,6). Flavonoids have anti-inflammatory (7), anti-

allergy (8), anti-diabetes, antihyperlipidemic and anti-hypercholesterolemic effects (9,10) and improves spatial memory (11). Phthalides constitute 70% of the *Kelussia* essence with several effects: liver protection, prostaglandin F2α inhibition, prevention of cancer tumors, treatment of epilepsy and liver disorders and reduction in blood viscosity (5,12,13). Despite this, there are no study related to the antileishmanial effect of the essential oil of *K. odoratissima*, this being the focus of our study.

Leishmaniasis affects more than 12 million people in 88 countries (14). Cutaneous leishmaniasis (CL), with 1 to 1.5 million annual cases, is the most common form of this disease (15). There is no vaccine available against any form of leishmaniasis and chemotherapy is the only currently available treatment (16,17). The standard treatment for

\*Corresponding author: Khodadad Pirali Kheirabadi, Department of Pathobiology, Faculty of Veterinary Medicine, University of Shahrekord, Shahrekord, Iran. Tel: +98-3814424427, Email: [khpirali@yahoo.com](mailto:khpirali@yahoo.com)

CL is antimoniate, which requires long-term injections, and resistance is emerging, which cause high dose usage, resulting side effects (17,18).

The search for new, safe and inexpensive drugs to treat and control CL, especially anthroponotic CL, is needed. Conventional healers are usually cheap and sometimes more effective than chemical drugs (19).

In this study, the effect of the essential oil of *K. odoratissima* on promastigot form of *Leishmania major* was studied. The results obtained from this study help us to find the alternative natural drug instead of chemical ones.

## Materials and Methods

### Plant material

A wild-growing plant from Kogiluye and Buyer Ahmad province located in the southwest of Iran, was collected in April and May, 2012. The samples, which were identified and confirmed as *K. odoratissima* Mozaff, were deposited in the Herbarium of the Research Institute of Jahade Keshavarzi of Shahrekord, Iran.

### Isolation of the volatile oil

20 kg from aerial parts of the plant was dried in an oven equipped with warm air circulation. One hundred grams of the air-dried material was ground and powdered. The powder was subjected to hydro-distillation for 3 hours using a Clevenger-type system. Finally, 30 ml essential oil extracted. The oil was kept at 2°C to 4°C in a sealed brown vial.

### Chemical analysis of the oil

Analysis of the essential oil was performed on a Hewlett-Packard Model 6890 GC-MS using a HP-5MS capillary column (30 m×0.25 mm i.d., 0.25 μm film thickness). The injector temperature and detector temperature was 250°C. Helium was used as the carrier gas at a flow rate of 1.00 ml/min. The column temperature was programmed from 40°C to 280°C at a rate of 4°C/min. The EI mode was at 70 eV, while the mass spectra were recorded from 30 to 450 m/z. Confirmation of identity was carried out by comparing their retention indices with the Wiley 275 library data of the GC-MS system and with the mass spectra literature data (20).

### Preparing the promastigot form of *Leishmania major*

The promastigot form of *Leishmania major* strain MRHO/IR/ER/75 was prepared from department of Parasitology Research, University of Medical Sciences of Isfahan, Iran.

The promastigots were transferred to RPMI 1640 medium and incubated at 26°C for 72 hours.

### Preparing the different concentrations and control groups

After the promastigots increased in the medium, they were counted using a Neobar chamber (0.100 mm, Tiefe, Depth, Profondeur, Neubauer Improved, Precicolor, HBG, Germany) in which 10 μl of this medium was mixed with 10 μl of formalin, which was used to kill the promastigots. 150 μl of medium contained 10<sup>6</sup> promastigots. Next, different concentrations of *K. odoratissima* essential oil (15, 30, 50, 75 and 100 mg/ml) were prepared, to achieve this, various essential oil concentrations (7.5 μl, 15 μl, 25 μl, 35.25 μl, 50 μl) were added to parasites. There was a negative control (no essential oil) and a positive control (Glucantime<sup>®</sup>, Specia, Paris, France) by mixing with sterile RPMI 1640 medium in different tubes. 10<sup>6</sup> promastigots (i.e., 150 μl of medium containing promastigots) were added to each tubes, as presented in Table 1. The total volume of all tubes was 500 μl after mixing.

### Counting the number of living promastigots after the mixing

After mixing the promastigots with different concentrations of *K. odoratissima* essential oil, those tubes, as well as the negative and positive controls, were incubated in dark incubator and in 26°C for 72 hours. The number of living promastigots was counted at 24, 48 and 72 hours after incubation.

### Statistical analysis

The data were analyzed by one-way analysis of variance (ANOVA) and significant differences (P<0.05) between means were assessed by Tukey's test using SPSS software version 19.0.

## Results

### Composition of essential oil

In the essential oil of *K. odoratissima*, the sesquiterpene hydrocarbons were the most abundant compounds (57.77%). In addition, the least quantitative percentage (2.7%) was belonged to monoterpene hydrocarbons. The major components were Z-ligustilide (34.5%), E-ligustilide (11.79%), 3-Z-butylidene-phthalide (8.81%) and Dec-9-en-1-ol (5.86%).

### 24 and 48 hours after incubation

Effects of essential oil of *Kelussia odoratissima* Mozaff on promastigot form of *Lishmania major* differed from

**Table 1.** Volume of materials in each tube prepared for different concentrations of essential oil

Tubes Materials	15 mg/ml	30 mg/ml	50 mg/ml	75 mg/ml	100 mg/ml	Negative control	Positive control (Glucantime)
Promastigots	150 μl	150 μl	150 μl	150 μl	150 μl	150 μl	150 μl
RPMI 1640	342.5 μl	335 μl	325 μl	314.75 μl	300 μl	350 μl	181 μl
Glucantime	-	-	-	-	-	-	169 μl
Essential oil	7.5 μl	15 μl	25 μl	35.25 μl	50 μl	-	-
Total volume	500 μl	500 μl	500 μl	500 μl	500 μl	500 μl	500 μl

**Table 2.** Mean number of living promastigots  $\pm$  SEM 24, 48 and 72 hours after incubation

Tube	Mean number of living promastigots $\pm$ SEM						Negative Control	Positive Control
	15 mg/ml	30 mg/ml	50 mg/ml	75 mg/ml	100 mg/ml			
24 h	127.25 $\pm$ 3.12 a	119.11 $\pm$ 4.54 a	116.63 $\pm$ 3.96 a	111.76 $\pm$ 4.32 a	103.51 $\pm$ 3.81 a	125.3 $\pm$ 1.96 b	79.47 $\pm$ 0.44 c	
48 h	124.12 $\pm$ 2.68 a	117.63 $\pm$ 2.96 a	110.17 $\pm$ 4.23 a	104.00 $\pm$ 3.69 a	98.99 $\pm$ 1.99 a	148.25 $\pm$ 2.25 b	74.23 $\pm$ 0.97 c	
72 h	119.08 $\pm$ 1.75 a	102.45 $\pm$ 1.85 a	93.27 $\pm$ 2.17 a	87.00 $\pm$ 4.44 a	73.93 $\pm$ 3.12 d	211.63 $\pm$ 2.19 b	67.56 $\pm$ 0.82 c	
Mean of 3 Times	123.48 $\pm$ 2.51 a	113.06 $\pm$ 3.11 b	106.69 $\pm$ 3.45 c	100.92 $\pm$ 4.15 d	92.14 $\pm$ 2.97 e	161.72 $\pm$ 2.13 f	73.75 $\pm$ 0.74 g	

Different letters within each row (i.e., within each time interval) indicate significant differences ( $P < 0.05$ ) between mean of living promastigots number in each tube according to Tukey's test.

negative control and positive controls. However, there were no significant differences between groups with different concentrations of essential oil (Table 2).

#### 72 hours after incubation

In this time decreasing in living promastigots in different tubes were more than past times. Same as past times, effect of essential oil of *Kelussia odoratissima* Mozaff on promastigot form of *Lishmania major* was differenced from negative control and positive control (Table 2).

Totally the *K. odoratissima* essential oil had a different effect on the promastigot form of *L. major* relative to the negative and positive control, but this depended on the essential oil concentration; higher concentrations (35.25  $\mu$ l, 50  $\mu$ l) had a stronger effect on promastigots, causing total mortality (Table 2). In all three-time intervals, the use of any concentration of essential oil of *Kelussia odoratissima* controlled *L. major* more effectively by increasing in essential oil concentration (Table 2).

#### Discussion

The application of natural plant products for control of bacterial, fungal and parasitic bee and brood diseases has several advantages over conventional means. In the specialized literature resistance of bacteria to essential oils has not yet been documented. In addition, natural substances in bee products decompose rapidly, their quantity in honey is low and they do not have an adverse effect on the health of consumers (21). Although in small amounts, essential oils and organic acids are normally contained in various types of honey. According to some authors their use as alternative means for prevention and control of bee diseases guarantees ecologically clean bee products (22).

This study showed antileishmanial effects of *Kelussia odoratissima* Mozaff essential oil on promastigot form of *Leishmania major*. The current treatment regimens for leishmaniasis, which are based on chemotherapy, are limited and are not ideal because they are often associated with severe side effects (23). In a case report from France, successful treatment of a 10-year-old boy with cutaneous leishmaniasis (*L. major*) was reported with oral azithromycin (24).

Pentavalent antimonials remain the drug of choice for the treatment of cutaneous and mucocutaneous leishmaniasis. Despite its availability in health facilities, its high toxicity and its parenteral use are limiting factors for the proper

treatment of cases of CL. It should be noted that most of these cases occur in areas of difficult access, in rural areas, which complicates the parenteral application of the drug and monitoring of its side effects. Treatment of CL with the drugs currently available represents an obstacle to proper clinical handling of the cases of leishmaniasis, and efforts should be made in order to add the promising drugs to clinical trials and investigate the use of new alternative drugs (25).

Traditional alternatives to antimonials used in unresponsive cases are amphotericin B, which cause serious, toxic side-effects (26,27), and the emergence of drug-resistant parasites is a major problem (17). These limitations and factors emphasize the urgent need for new, inexpensive, safe and easy-to-administer substances for the treatment of this infectious disease, possibly through the form of traditional medicines which represent the accumulation of practices based on theories, beliefs and experiences of different cultures over a wide period of time (28).

Amphotericin B is the second drug of choice when antimonials fail or cannot be used. However, they are toxic and expensive drugs, which often require hospitalization for their administration (29). An alternative to the treatment with conventional amphotericin B is the use of liposomal amphotericin B, which has higher peak plasma levels and lower toxicity (30).

Traditional medicines are used for the maintenance of health and in the prevention, diagnosis, improvement and treatment of illnesses (31). Based on traditional medicine, new drugs of herbal origins discovered through ethnopharmacological studies have shown promising results.

#### Conclusion

By considering an increase in drug resistance against leishmania, it is possible to use the essential oil of *Kelussia odoratissima* instead of chemical drugs. The use of any concentration of essential oil of *Kelussia odoratissima* controlled *L. major* more effectively by increasing in essential oil concentration. Future research would assess the effect of this essential oil on the amastigote form of *L. major*.

#### Acknowledgments

Work in the laboratory was supported by University of Shahrekord. I would like to thank all of persons who help

us to do this research.

#### Authors' contributions

All the authors wrote the manuscript equally.

#### Conflict of interests

The authors declared no competing interests.

#### Ethical considerations

Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors.

#### Funding/Support

This research was financially supported by Shahrekord University, Shahrekord, Iran.

#### References

- Kelmanson JE, Jager AK, Van Staden J. Zulu medicinal plants with antibacterial activity. *J Ethnopharmacol* 2000; 69: 2416.
- Srinivasan D, Sangeetha N, Suresh T, Perumalsamy PL. Antimicrobial activity of certain Indian medicinal plants used in folkloric medicine. *J Ethnopharmacol* 2001; 74: 217-20.
- Fazeli MR, Amin GH, Ahmadian AM, Ashtiani H, Jamalifar H, Samadi N. Antimicrobial activities of Iranian sumac and avishan-e-shirazi (*Zataria multiflora*) against some food-borne bacteria. *Food Control* 2007; 18: 646-9.
- Ahmadi F, Kadivar M, Shahedi M. Antioxidant activity of *Kelussia odoratissima* Mozaff. in model and food systems. *Food Chem* 2007; 105: 57-64.
- Tehrani Z. Phytochemical chemical study on *Kelussia odoratissima* Mozaffarian: Pharmacy thesis. School of Pharmacy, Isfahan University of Medical Sciences. 1999; 42-48.
- Gandomkar M. Phytochemistry of the essential oil of wild celery plant: Pharmacy thesis. School of Pharmacy, Isfahan University of Medical Sciences. 1999; 37-41.
- Asgari S, Naderi GA, Garipour M, Dashti G, Sadjadian RA. Effect of *Amirkabiria odoratissima* on the development and progression of atherosclerosis in hypercholesterolemic rabbits. *Iranian Journal of Diabetes and Lipid Disorders* 2003; 3(1): 88-3.
- Hashemi V, Ghannadi A, Soltani RL. Analgesic and anti-inflammatory effects of *Amirkabiria odoratissima*. *Journal of Research in Medical Sciences* 2003; 7(4): 121-5.
- Asgari S, Naderi GA, Jafariyan A, Askari N, Behagh AR. Fibrinolytic activity of *Amirkabiria odoratissima* Mozaffarian. *Journal of Medicinal Plants* 2005; 4(13): 19-25.
- Roghani M, Baluchnejadmojarad T, Ramazani M. The effect of chronic oral feeding of *Apium graveolens* on learning and memory in diabetic rats. *Journal of Medicinal Plants* 2008; 7(27): 98-105.
- Cao YX, Zhang W, He JY, He LC, Xu CB. Ligustilide induces vasodilatation via inhibiting voltage dependent calcium channel and receptor-mediated  $Ca^{2+}$  influx and release. *Vascul Pharmacol* 2006; 45: 171-6.
- Craker LE. Herbs species and medicinal plants. Encanto. Oxyx Press 1984; 2: 15-6.
- Beck J. Investigation of the bioactive constituents of several herbal medicines [Doctoral dissertation]. Colorado State University; 1996.
- WHO. Leishmaniasis. The global trend. [Accessed 30 January 2009]. [http://www.who.int/neglected\\_disease/integrated-media/Leishmaniasis/en/index.html](http://www.who.int/neglected_disease/integrated-media/Leishmaniasis/en/index.html)
- Desjeux P. Leishmaniasis: Current situation and new perspectives. *Comp. Immunol Microbiol Infect Dis* 2004; 27: 305-18.
- Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasser K, Modabber F. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis-A meta-analysis. *Vaccine* 2009; 27: 474-5.
- Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. *Clin Microbiol Rev* 2006; 19: 111-26.
- Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, et al. Glucantime-resistant *Leishmania tropica* isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. *Parasitol Res* 2007; 101: 1319-22.
- Sandhu DS, Heinrich M. The use of health foods, spices and other botanicals in the Sikh community in London. *Phytother Res* 2005; 19: 633-42.
- Adams RP. Identification of Essential Oil Components by Gas Chromatography/Quadrupole Mass Spectroscopy. 3rd ed. Carol Stream, IL: Allured Publishing Corporation; 2001. p. 456.
- Nozal MJ, Bernal JL, Jiménez JJ, González MJ, Higes M. Extraction of thymol, eucalyptol, menthol, and camphor residues from honey and beeswax. Determination by gas chromatography with flame ionization detection. *Journal of Chromatography A* 2002; 19: 207-15.
- Zhelyazkova I, Gurgulova K, Malinova K, Ali AS. Investigation on the sti-mulating effect of plant preparations "Green TM" and "Ecophyl-P" upon bee families development. In: Proceedings of the International Scientific Conference. 2009; Union of Scientists Stara Zagora.
- Tasdemir D, Kaiser M, Brun R, Yardley V, Schmidt TJ, Tosun F, Rüedi P. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. *Antimicrob. Agents Chemother* 2006; 50(4): 1352-64.

24. Minodier P, Zambelli L, Mary C, Faraut F, Garnier JM, Berbis P. Cutaneous leishmaniasis treated with azithromycin in a child. *Pediatr Infect Dis J* 2008; 27 (1): 80-1.
25. Basano AS, Camargo LM. [American cutaneous leishmaniasis: history, epidemiology and prospects for control]. *Rev Bras Epidemiol* 2004; 7: 328-37.
26. Sereno D, Holzmuller P, Lemesre JL. Efficacy of second line drugs on antimonyl-resistant amastigotes of *Leishmania infantum*. *Acta Trop* 2000; 74: 25-31.
27. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. *Ind J Med Res* 2006; 123: 399-410.
28. Fennel CW, Makunga NP, Van Staden J. Medicinal plants and biotechnology: An integrated approach to healthcare. In: Teixeira da Silva JA, (Ed.). *Floriculture, Ornamental and Plant Biotechnology: Advances and Topical Issues*. 1st ed. Isleworth, UK: Global Science Books, Ltd.; 2006. p. 41-53.
29. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Mobabber F. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed *Leishmania (Leishmania) amazonensis* vaccine plus antimonial. *Int J Dermatol* 2002; 41: 73-8.
30. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. *Clin Infect Dis* 1997; 24: 684-703.
31. Firenzuoli F, Gori L. Herbal Medicine Today. *Clinical and Research* 2007; 4(S1): 37-40.

Archive of SID